Topics

Human medicines European public assessment report (EPAR): Odefsey, emtricitabine / rilpivirine / tenofovir alafenamide, HIV Infections, Date of authorisation: 21/06/2016, Revision: 14, Status: Authorised

07:20 EDT 16 Aug 2019 | European Medicines Agency

Human medicines European public assessment report (EPAR): Odefsey, emtricitabine / rilpivirine / tenofovir alafenamide, HIV Infections, Date of authorisation: 21/06/2016, Revision: 14, Status: Authorised

Original Article: Human medicines European public assessment report (EPAR): Odefsey, emtricitabine / rilpivirine / tenofovir alafenamide, HIV Infections, Date of authorisation: 21/06/2016, Revision: 14, Status: Authorised

NEXT ARTICLE

More From BioPortfolio on "Human medicines European public assessment report (EPAR): Odefsey, emtricitabine / rilpivirine / tenofovir alafenamide, HIV Infections, Date of authorisation: 21/06/2016, Revision: 14, Status: Authorised"

Quick Search

Relevant Topic

Reverse Transcriptase
Reverse transcriptase (RT) is an enzyme used to generate complementary DNA (cDNA) from an RNA template, a process termed reverse transcription. It is mainly associated with retroviruses. RT inhibitors are widely used as antiretroviral drugs. RT activitie...